In the News

20 May 2019
UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.

Publication: UCB

The FDA has approved midazolam, the first nasal spray to treat intermittent, stereotypic episodes of frequent seizure activity for individuals living with epilepsy. Midazolam was initially developed by SV Health Investors portfolio company Ikano Therapeutics, Inc. before being acquired by UCB.

View the article

UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.